XML 35 R23.htm IDEA: XBRL DOCUMENT
v3.19.2

Significant Collaboration and Licensing Agreements - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions | 1 Months Ended | 3 Months Ended | 6 Months Ended
--- | --- | --- | ---
Feb. 28, 2017 | Mar. 31, 2015 | Jun. 30, 2010 | Mar. 31, 2019 | Jun. 30, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |
Equity investment fair value amount |  |  |  |  | $ 77,365
Voyager Therapeutics | Collaboration and License Agreement |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |
Up-front cash payable |  |  |  |  | 115,000
Collaborative agreement equity investment amount |  |  |  |  | $ 50,000
Share price |  |  |  |  | $ 11.9625
Equity investment fair value amount |  |  |  |  | $ 54,700
Collaboration termination notice period |  |  |  |  | 180 days
Voyager Therapeutics | Collaboration and License Agreement | IPR&D |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |
Up-front cash payable |  |  |  |  | $ 5,000
Collaborative agreement remaining purchase price |  |  |  | $ 113,100 |
Voyager Therapeutics | Collaboration and License Agreement | Common Stock |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |
Common stock issued for collaboration agreement |  |  |  |  | 4.2
Voyager Therapeutics | Collaboration and License Agreement | Development, Regulatory and Commercial Milestone Payment |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |
Potential milestone payments |  |  |  |  | $ 1,700,000
B I A L |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |
Up-front license fees | $ (30,000) |  |  |  |
B I A L | Regulatory and Clinical Results and FDA Acceptance Milestones |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |
Potential milestone payments |  |  |  |  | 10,000
B I A L | Development and Regulatory Milestone Payments |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |
Collaborative agreement maximum additional payment to receive |  |  |  |  | 40,000
Collaborative agreement payment received |  |  |  |  | 10,000
B I A L | Commercial Milestone Payments |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |
Collaborative agreement maximum additional payment to receive |  |  |  |  | 75,000
Mitsubishi Tanabe |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |
Up-front license fees |  | $ 30,000 |  |  |
Collaborative agreement maximum additional payment to receive |  | 85,000 |  |  |
Revenues recognized under collaboration agreement |  | 19,800 |  |  |
Deferred revenues under collaboration |  | 10,200 |  |  |
Mitsubishi Tanabe | Phase II/III Clinical Trials |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |
Revenues recognized under collaboration agreement |  | $ 15,000 |  |  |
AbbVie |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |
Up-front license fees |  |  | $ 75,000 |  |
AbbVie | Development and Regulatory Milestone Payments |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |
Collaborative agreement maximum additional payment to receive |  |  |  |  | 480,000
Collaborative agreement payment received |  |  |  |  | 115,000
AbbVie | Commercial Milestone Payments |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |
Collaborative agreement maximum additional payment to receive |  |  |  |  | $ 50,000

X
- Definition Milestone revenue, sponsored research and development, and amortization of up front licensing fees recognized during the period under a collaborative agreement with a third-party. + References No definition available. + Details
Name: | nbix_CollaborationRevenue
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative agreement remaining purchase price includes transaction costs. + References No definition available. + Details
Name: | nbix_CollaborativeAgreementRemainingPurchasePriceIncludesTransactionCosts
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of contingent consideration received as a result of satisfying a condition or requirement of a collaborative agreement. + References No definition available. + Details
Name: | nbix_CollaborativeArrangementContingentPaymentReceived
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative arrangement equity investment amount. + References No definition available. + Details
Name: | nbix_CollaborativeArrangementEquityInvestmentAmount
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The maximum amount of contingent payments received under collaborative arrangements. + References No definition available. + Details
Name: | nbix_CollaborativeArrangementMaximumContingentPaymentsAmount
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative arrangement upfront cash payable. + References No definition available. + Details
Name: | nbix_CollaborativeArrangementUpfrontCashPayable
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Up front payments received (paid) under collaborative agreements for sponsored research and development, and licensing fees + References No definition available. + Details
Name: | nbix_CollaborativeArrangementUpfrontPaymentReceivedPaid
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of potential milestone payments to be paid under a license agreement. + References No definition available. + Details
Name: | nbix_PotentialMilestonePayments
Namespace Prefix: | nbix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of time required for third party collaborator to give written notice prior to terminating the collaborative agreement. + References No definition available. + Details
Name: | nbix_TerminationNoticePeriod
Namespace Prefix: | nbix_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References No definition available. + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of restricted investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 860 -SubTopic 30 -Section 50 -Paragraph 1A -Subparagraph (b)(1)(i) -URI http://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729 + Details
Name: | us-gaap_EquitySecuritiesFvNiRestricted
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Balance held at close of period in number of shares. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section 50 -Paragraph 6 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14.Column B) -URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 4 -Subparagraph (SX 210.12-12C.Column B) -URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12.Column B) -URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010 + Details
Name: | us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_VoyagerTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nbix_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nbix_ClinicalDevelopmentRegulatoryAndCommercialMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_BIALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nbix_RegulatoryApprovalClinicalResultsAndFdaAcceptanceMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nbix_ClinicalDevelopmentAndRegulatoryMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nbix_CommercializationEventsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_MitsubishiTanabePharmaCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nbix_PhaseTwoAndThreeClinicalTrialsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_AbbvieIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=nbix_ClinicalDevelopmentAndRegulatoryMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=nbix_CommercializationEventsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |